

Haematologica  
HAEMATOL/2018/214809  
Version 3

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

Simone Claudiani, Aoife Gatenby, Richard Szydlo, George Nesr, Adi Shacham Abulafia, Renuka Palanikawandar, Georgios Nteliopoulos, Jamshid Khorashad, Letizia Foroni, Jane F. Apperley, and Dragana Milojkovic

Disclosures: S.C. Honoraria from Incyte and Pfizer; G.N. Honoraria from Incyte; A.S.A.: Novartis advisory board; J.F.A. Honoraria from Pfizer, BMS, Incyte and Novartis; research funding from Ariad and Pfizer; D.M. Honoraria from Pfizer, BMS, Incyte and Novartis.

Contributions: S.C. developed the study, collected, analyzed and interpreted the data and wrote the manuscript; J.F.A. developed the study, interpreted data and wrote the manuscript; A.G. collected the data; R.S. developed the study and analyzed the data; G.N., A.S.A., R.P., G.Nt., J.K., L.F. and D.M. revised and approved the final version of the manuscript.